Company Quick10K Filing
Biomarin Pharmaceutical
10-K 2019-12-31 Filed 2020-02-27
10-Q 2019-09-30 Filed 2019-10-29
10-Q 2019-06-30 Filed 2019-08-02
10-Q 2019-03-31 Filed 2019-04-29
10-K 2018-12-31 Filed 2019-02-28
10-Q 2018-09-30 Filed 2018-10-26
10-Q 2018-06-30 Filed 2018-08-03
10-Q 2018-03-31 Filed 2018-04-27
10-K 2017-12-31 Filed 2018-02-26
10-Q 2017-09-30 Filed 2017-10-31
10-Q 2017-06-30 Filed 2017-08-02
10-Q 2017-03-31 Filed 2017-05-04
10-K 2016-12-31 Filed 2017-02-27
10-Q 2016-09-30 Filed 2016-11-03
10-Q 2016-06-30 Filed 2016-08-08
10-Q 2016-03-31 Filed 2016-05-02
10-K 2015-12-31 Filed 2016-02-29
10-Q 2015-09-30 Filed 2015-11-02
10-Q 2015-06-30 Filed 2015-08-05
10-Q 2015-03-31 Filed 2015-05-05
10-K 2014-12-31 Filed 2015-03-02
10-Q 2014-09-30 Filed 2014-10-28
10-Q 2014-06-30 Filed 2014-07-31
10-Q 2014-03-31 Filed 2014-05-02
10-K 2013-12-31 Filed 2014-02-26
10-Q 2013-09-30 Filed 2013-10-28
10-Q 2013-06-30 Filed 2013-07-29
10-Q 2013-03-31 Filed 2013-04-29
10-K 2012-12-31 Filed 2013-02-26
10-Q 2012-09-30 Filed 2012-10-29
10-Q 2012-06-30 Filed 2012-08-02
10-Q 2012-03-31 Filed 2012-04-30
10-K 2011-12-31 Filed 2012-02-22
10-Q 2011-09-30 Filed 2011-10-31
10-Q 2011-06-30 Filed 2011-08-01
10-Q 2011-03-31 Filed 2011-04-29
10-K 2010-12-31 Filed 2011-02-24
10-Q 2010-09-30 Filed 2010-10-29
10-Q 2010-06-30 Filed 2010-08-04
10-Q 2010-03-31 Filed 2010-05-03
10-K 2009-12-31 Filed 2010-02-26
8-K 2020-02-26 Earnings, Exhibits
8-K 2020-01-28 Officers
8-K 2019-08-01 Earnings, Exhibits
8-K 2019-07-08 Officers
8-K 2019-06-04 Officers, Shareholder Vote
8-K 2019-04-25 Earnings, Exhibits
8-K 2019-02-21 Earnings, Exhibits
8-K 2019-01-07 Earnings, Exhibits
8-K 2018-10-25 Earnings, Exhibits
8-K 2018-10-19 Enter Agreement, Leave Agreement, Off-BS Arrangement
8-K 2018-09-19 Amend Bylaw, Exhibits
8-K 2018-08-02 Earnings, Exhibits
8-K 2018-06-05 Shareholder Vote
8-K 2018-04-25 Earnings, Exhibits
8-K 2018-02-22 Earnings, Exhibits

Biomarin Pharmaceutical Financials

BMRN Metrics, Comps, Filings

Quarterly | Annual

Business

BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products.

Our portfolio consists of several commercial products and multiple clinical and pre-clinical product candidates for the treatment of various diseases. We continue to invest in our clinical and pre-clinical product pipeline by committing significant resources to research and development programs and business development opportunities within our areas of scientific, manufacturing and technical expertise.

A summary of our major commercial products is provided below:


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Quarterly)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152
Bausch (BHC) 7,760 0% 25.3 -1% 31,667 29,107 8,498 0 -266 1,216 30,774
Alnylam Pharmaceuticals (ALNY) 8,913 80% -9.7 -32% 2,542 935 169 135 -821 -820 7,987
Catalent (CTLT) 7,405 32% 23.8 2% 6,120 3,864 2,631 834 152 421 10,021
Jazz Pharmaceuticals (JAZZ) 7,549 21% 11.2 11% 5,528 2,473 2,056 441 609 762 8,530
Dr Reddys Laboratories (RDY) 6,726 0% 225,427 85,230 0 0 0 0 6,714
Perrigo (PRGO) 7,421 37% 17.9 2% 11,311 5,552 4,710 1,735 247 580 10,388
Amarinuk (AMRN) 5,417 61% -75.7 -7% 867 271 364 221 -63 -63 4,799
Nektar Therapeutics (NKTR) 3,147 81% -7.6 -20% 2,088 600 121 98 -425 -401 3,065
Array Biopharma (ARRY) 5,260 92% -43.6 -22% 567 265 240 221 -126 -114 4,960
Galapagos (GLPG) 5,015 0% 1,439 225 0 0 0 0 5,015
Loxo Oncology (LOXO) 4,868 0% 697.4 1% 659 280 124 0 7 7 4,732
Blueprint Medicines (BPMC) 3,599 0% -8.5 -49% 738 222 16 0 -362 -354 3,005
Horizon Pharma (HZNP) 5,349 71% 26.5 2% 3,721 2,166 1,292 915 68 222 5,880

Balance Sheet ($MM)2010-06-302010-09-302010-12-312011-03-312011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash1161288891113714683178181181154175182569640585398875901441376397270306707408348355431598474427882494364308423
Accounts Receivable787987106107107105106101117109120115125118110122121144176186149165181214216215230238252261318364384343393377403
Inventory8492110110112116130124120121129136142149163177193204199223238262272297327347355384430457476468473508531535579609
PP&E2132142222183163743853883994144344394494625046326757037527788218709831,0111,0351,0581,1411,1821,2231,2691,3031,3221,3411,3851,4211,4461,4781,505
Assets9861,2451,2631,2641,2801,2951,3041,2971,5331,5671,6021,5981,6021,6212,2492,3412,3462,4402,4903,6593,6493,6253,7293,6673,0873,8424,0243,9394,0204,5814,6334,5974,6254,6954,4274,4354,3934,558
Accounts Payable77121213112425161637152238332426
Long-Term Debt156156870870870870
Liabilities6236595455435485215315255325525863483433449088818849329631,2331,2921,3321,3291,3771,1701,1961,2571,1701,2241,7671,8241,7901,7401,7801,4591,4991,4321,484
Stockholders' Equity3635867177217327757737721,0001,0151,0161,2501,2581,2761,3411,4601,4621,5081,5282,4252,3572,2932,4012,2901,9182,6462,7662,7692,7962,8142,8092,8072,8852,9152,9682,9372,9613,074
Income Statement ($MM)2010-06-302010-09-302010-12-312011-03-312011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue9298102109122113108117124128132128137137147152206177231203251209228237300280300304317334358373373392401388461
Cost of Revenue14182021222222172425272023282523313046334037434352516450565976827979897797
Gross Profit788081891009186100100103105107114109122129175147185170211172185194249229236254261275282291294313312310364
R&D363942455959587493668484103889786108126142142158159176159167161175145143154169184176161184186173
SG&A3738424144454845524655515162726068751009310294114105110119143120144131160138153149162161170
Tax12154112311131339-441-102473-159-24-136-95212314-4-45
Net Income-0217-12-4-5-18-27-24-32-5-53-40-22-53-62-38-347-70-68-82-9169-85-424-43-79-16-37-13-51-44-17-13-56-3755
Cash Flow ($MM)2010-06-302010-09-302010-12-312011-03-312011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating9-16-3149-0-7-11412-32-7-9-11-27-8-27-138-13-3-68-172-46-110-80193815-43-3447-55-2470
Cash Investing-4-1431-58-3530-152-21-52-8123-306-39-187461-751-445-63807776-327-31025-40-430140-72402-502049
Cash Financing7-1038810132491040141612705137943915-2412-37873719-71948213-105-25-52-2